About
The Industry’s Only Meeting Dedicated to Improving Genome Editing Analytical Development
As the gene editing field continues to grow, analytical teams continue to strive towards gold standards for analytical technologies and assays.
By fostering a collaborative approach to this challenge, the 2024 summit presented attendees with the latest insights and strategic direction from industry leaders, helping them overcome three key challenges facing both early- and late- stage analytical, and quality control strategies:
Characterization of guides, nucleases, delivery vehicles, and full drug constructs
Robust non-clinical and CMC assay development, including biodistribution studies, potency assays, and on-/off- target sequencing detection, nomination, and quantification
Meeting regulatory expectations for analytical data to successfully support IND submissions
Attendees leveraged the latest data and technological advancements, engaged in co-operative roundtables led by topic key opinion leaders, and built connections with industry thought leaders, with presenting groups from the likes of Beam Therapeutics, Editas Medicine, NIST, Nvelop Therapeutics, Prime Medicine, Vertex Pharmaceuticals and Verve Therapeutics.
Join your peers in 2025 for a one-stop shop in the latest analytical development expertise, bolstering the safety, efficacy, and regulatory compliance of your gene editing programs.
Industry-Leading Gene Editing Conferences
At Hanson Wade, we have over 10 years of experience in industry-focused gene editing conferences, spanning technology innovation, drug development, agricultural products, and analytical development. We pride ourselves on bringing together the foremost voices on these topics to lead collaborative discussions around the key challenges facing industry in these respective fields.
Don’t just take it from us though. Here are what our previous attendees have had to say:
“High quality attendees with very relevant presentations” – Thermo Fisher Scientific
“Invaluable information sharing and networking that will accelerate the advancement of therapeutic gene editing” – Scribe Therapeutics
“Excellent agenda; outstanding speakers; critically important topics were discussed” – Wiley
“Top notch, cutting-edge speakers discussing the cutting-edge applications of CRISPR” – Bayer
“It was an excellent forum to hear from and network with peers in the field” – ReCode Therapeutics
Who Would You Have Met?
The 2nd CRISPR-Based Therapy Analytical Development Summit was dedicated to enhancing the quality and diversity of analytical tools for genome editing therapies, attracting a niche audience of industry analytical experts to ignite thought-provoking discussions that lead to long-term, mutually beneficial relationships in a rapidly evolving field.
This was the only industry-led event dedicated to covering all challenges associated with analytical development specifically for drug developers. Uniting 50+ Analytical Development, Analytical Sciences, Bioassay, Process Development, Quality Control, and Business Development leaders, this summit combined both strategic and technical content to provide actional insights for assay developers working across all drug development stages.
